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ABSTRACT
Background: The percutaneous treatment of coronary artery 
disease has been revolutionized by the use of drug-eluting 
stents (DES). However, its use in the daily practice involves 
patients with more complex clinical and angiographic charac-
teristics than those found in randomized trials. This registry was 
designed to characterize diabetic patients and their outcomes 
following DES implantation in our country. Methods: Prospec-
tive single-center registry enrolling consecutive patients after 
DES implantation. Clinical, angiographic and procedurerelated 
data, as well as early and long-term outcomes were recorded. 
The primary endpoint, including cardiac death, myocardial 
infarction or target lesion revascularization, was compared 
between diabetics and non-diabetics. Results: We evaluated 
1,670 patients treated with DES from 2002 to 2012 with a 
follow-up of 3.2 ± 2.5 years. One third of the patients were 
diabetic and had lower event-free survival when compared 
to non-diabetic patients (79.4% vs. 82.6%; P = 0.015). The 
adjusted odds ratio, however, was 1.22 (95% CI, 0.89-1.69) 
and was not significant. A significantly lower event-free survival 
was observed in the subgroup of patients receiving insulin, 
whereas it was similar for diabetic and nondiabetic patients 
in the subgroup not receiving insulin (68.7% vs. 83.9% 
vs. 82.8%, respectively; P < 0.01). The adjusted odds ratio 
was 1.72 (95% CI, 1.13-2.63) higher for diabetic patients 
receiving insulin when compared to the remaining patients. 
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RESUMO
Resultados Iniciais e Tardios de Diabéticos Tratados 
com Stents Farmacológicos do Registro Safira
Introdução: O tratamento percutâneo da doença arterial coro-
nária foi revolucionado pelo uso dos stents farmacológicos (SF). 
No entanto, sua utilização na prática diária envolve pacientes 
com características clínicas e angiográficas mais complexas 
dos que aquelas encontradas em estudos randomizados. Este 
registro se propôs a caracterizar, em nosso meio, diabéticos e 
seus desfechos clínicos após implante de SF. Métodos: Registro 
unicêntrico, prospectivo, que arrolou pacientes consecutivos 
submetidos a implante de SF. Foram registrados dados clínicos, 
angiográficos e do procedimento, assim como os desfechos 
hospitalares e tardios. A avaliação do desfecho primário, 
composto por óbito cardíaco, infarto agudo do miocárdio ou 
revascularização da lesão-alvo, foi realizada comparando-se 
pacientes diabéticos e não diabéticos. Resultados: Avaliamos 
1.670 pacientes tratados com SF no período de 2002 a 2012, 
com seguimento de 3,2 ± 2,5 anos. Um terço dos pacientes 
era diabético e apresentou sobrevivência livre de eventos 
menor que os não diabéticos (79,4% vs. 82,6%; P = 0,02). 
A razão de risco ajustada, no entanto, foi de 1,22 (IC 95%, 
0,89-1,69) - não significativa. Ao analisar o subgrupo dos 
pacientes em uso de insulina, encontramos sobrevivência 
livre de eventos significativamente menor que a dos demais, 
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Conclusions: The use of DES is beneficial for all diabetic 
patients, especially those who do not receive insulin.
 
 
 
 
 
DESCRIPTORS: Coronary disease. Diabetes mellitus, type 2. 
Drug-eluting stents. Percutaneous coronary intervention.
and those who refused to sign the informed consent 
were excluded.
Procedure and antiplatelet therapy
Percutaneous coronary interventions (PCIs) were 
performed according to the technique recommended 
by the guidelines.7 The choice of the stent was left to 
the surgeons’ discretion.
The antiplatelet protocol consisted of a combination 
of two antiplatelet agents, acetylsalicylic acid (ASA) and 
a P2Y12 inhibitor. ASA was used at a loading dose of 
200 mg and 100 mg for maintenance; clopidogrel was 
used at a loading dose of 300-600 mg and 75 mg for 
maintenance. With the availability of ticagrelor and 
prasugrel, these drugs have been incorporated into 
clinical practice at loading doses of 60 and 180 mg, 
and maintenance at 90 mg twice daily and 10 mg, 
respectively. The P2Y12 inhibitors have been recom-
mended for a minimum period of one year. The use 
of glycoprotein IIb/IIIa inhibitors was at the discretion 
of the surgeon.
Definitions and primary outcome
The clinical follow-up was performed by medical 
consultation or telephone contact at 30 days, six months, 
one year, and annually thereafter. Adverse events were 
reviewed using data from medical records and reports 
from other hospitals where the adverse event occurred.
The diagnosis of diabetes was defined, in accordance 
with current consensus, as a fasting glucose ≥ 126 mg/dL, 
glycaemia ≥ 200 mg/dL two hours after ingestion of 75 g 
glucose (glucose tolerance test), random blood glucose ≥ 
200 mg/dL accompanied by symptoms of hyperglycaemia.8 
The patients were also classified according to whether or 
not they needed insulin treatment.
Deaths were considered of cardiac origin, unless a 
noncardiac cause could be unequivocally established. 
Acute myocardial infarction (AMI) was defined as an 
increase in creatine kinase fraction MB (CK-MB) superior 
to three times the upper limit of normal, with or without 
the appearance of new Q waves.9 Target vessel revas-
cularization (TVR) was defined as the ischemia-guided 
enquanto que os diabéticos que não estavam em uso de 
insulina mostraram comportamento semelhante ao dos não 
diabéticos (68,7% vs. 83,9% vs. 82,8%, respectivamente; P 
< 0,01). A razão de risco ajustada foi 1,72 (IC 95%, 1,13-
2,63) vez maior para os diabéticos em uso de insulina em 
comparação aos demais pacientes. Conclusões: O uso de SF 
traz benefícios para todos os diabéticos, especialmente para 
os que não utilizam insulina.
DESCRITORES: Doença das coronárias. Diabetes mellitus tipo 
2. Stents farmacológicos. Intervenção coronária percutânea.
T he technology that enabled the coating of metallic stents with drugs has revolutionized interventional cardiology. Drug-eluting stents (DES) have the 
ability to reduce neointimal hyperplasia, decreasing 
the coronary restenosis and the need for subsequent 
revascularizations.1 With such benefits, these new de-
vices have expanded the indications for percutaneous 
treatment for lesions and in more complex patients.2
However, despite their routine use, there are still 
doubts about the results of DES in the population 
that usually presents clinical and angiographic criteria 
not included in randomized clinical trials. Another 
important aspect to note is the lack of data from the 
Brazilian population, whose own cultural and social 
characteristics influence the adherence to treatment, 
besides the fact that its genetic composition differs 
from populations assessed in the large registries of the 
United States and Europe.3-6
The aim of the present study was to evaluate the 
initial and late events of a non-selected cohort of pa-
tients undergoing DES implantation, comparing diabetic 
and non-diabetic patients.
METHODS
This was a single-center prospective trial of con-
secutive patients with coronary artery disease treated 
with at least one DES from July 2002 to August 2012 in 
the Complexo Hospitalar, Real e Benemérita Sociedade 
Portuguesa de Beneficência, Hospitais São Joaquim e 
São José, and in the Interventionist Cardiology Ser-
vice Ariê, in the city of São Paulo, SP, Brazil. Patients 
were included in the study after explanation, reading, 
and signing of the informed consent. The protocol for 
this project was duly approved by the research ethics 
committee under number 778-12, as was the informed 
consent form.
Inclusion and exclusion criteria
Patients ≥ 18 years old, with indication for CABG 
regardless of clinical or angiographic picture, and who 
could be treated with available DES, were included. 
Patients with contraindications to the use of antiplatelet 
medication indicated by the pharmacological protocol 
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revascularization of the vessel treated at the index PCI, 
whether by new PCI or coronary artery bypass graft 
(CABG), in the presence of symptoms or ischemia 
during the noninvasive stratification. Angiographic 
success was defined as achieving a stenosis diameter 
< 20% and Thrombolysis in Myocardial Infarction (TIMI) 
3 flow. Procedural success was considered as angio-
graphic success free of occurrence of death, AMI, or 
urgent TVR. The definition of TIMI bleeding was used 
to classify possible bleeding.10
The primary outcome was considered as the oc-
currence of cardiovascular death, nonfatal AMI, or 
ischemia-driven TVR in the late phase.
Statistical analysis
Continuous variables were presented as means and 
standard deviations and were compared by Student’s 
t-test. Categorical variables were described as frequency 
and percentage, and were compared by the chi-squared 
or Fisher’s exact test, where appropriate. Cumulative 
event rates were estimated by the Kaplan-Meier method, 
and differences were compared by log-rank test. Patients 
were followed-up until the occurrence of an outcome, 
or censored in December 2012. Statistical significance 
was considered at a level of 5% (P  ≤  0.05).
Multivariate predictors of outcomes were tested using 
the proportional hazards model of Cox when they showed 
significant effects in the univariate model (P < 0.15). The 
predictors included in the model were age, gender, body 
mass index, hypertension, smoking state, dyslipidaemia, 
diabetes mellitus, prior AMI, previous stroke, peripheral 
vascular disease, previous revascularization, chronic renal 
failure, ventricular dysfunction, extent of coronary artery 
disease, treated vessel, type of injury, segmental or calcified 
TABLE 1 
Clinical and angiographic characteristics
Diabetics n = 540 Non diabetics n = 1,130 P
Age, years 63.9 ± 10.3 63.0 ± 11.7 0.11
Female, n (%) 175 (32.4) 298 (26.4) 0.01
BMI, kg/m2 28.6 ± 4.7 27.0 ± 4.3 < 0.01
Hypertension, n (%) 476 (88.2) 853 (75.5) < 0.01
Dyslipidaemia, n (%) 401 (74.3) 717 (63.5) < 0.01
Current smoking, n (%) 73 (13.5) 204 (18.1) < 0.01
Family history of CAD, n (%) 215 (39.8) 453 (40.1) 0.92
Prior AMI, n (%) 116 (23.0) 266 (23.5) 0.79
Prior stroke, n (%) 14 (2.6) 24 (2.1) 0.55
Previous PCI, n (%) 91 (16.9) 190 (16.8) 0.98
Previous CABG, n (%) 89 (16.5) 166 (14.7) 0.34
Chronic renal failure, n (%) 60 (11.1) 80 (7.1) < 0.01
Chronic lung disease, n (%) 4 (0.7) 17 (1.5) 0.19
Peripheral vascular disease, n (%) 24 (4.4) 23 (2.0) < 0.01
Clinical picture, n (%) 0.38
Silent ischemia 119 (22.0) 260 (23.1)
Stable angina 295 (54.6) 596 (52.8)
Unstable angina, low/moderate risk 46 (8.5) 127 (11.3)
Unstable angina, high-risk/ NSTE-MI 75 (13.9) 130 (11.5)
STE-MI 4 (0.5) 15 (1.3)
Extent of CAD 0.01
1 178 (33.0) 469 (41.5)
2 181 (33.6) 383 (33.9)
3 180 (33.3) 277 (24.5)
LV dysfunction, n (%) 0.25
Light 130 (60.2) 263 (62.6)
Moderate 61 (28.2) 117 (27.9)
Severe 25 (1.6) 40 (9.5)
BMI = body mass index; CAD = coronary artery disease; AMI = acute myocardial infarction; PCI = percutaneous coronary intervention; 
NSTE-MI = myocardial infarction without ST-segment elevation; STE-MI = myocardial infarction with ST-segment elevation; LV = left 
ventricle.
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lesions, treatment for venous and arterial grafts, stenosis 
diameter pre- and post-procedure, implantation technique 
of direct stent, and stent type.
Left ventricular dysfunction was defined according 
to a four-point scale (normal, mild dysfunction, mo-
derate dysfunction, or severe dysfunction). The results 
are presented as risk ratio (RR) and 95% confidence 
interval (95% CI). The proportional hazards assump-
tion was confirmed by testing Schoenfeld residuals; no 
violations were found.
All analyses were performed using Stata (StataCorp 
– Texas, USA), version 12.
TABLE 2 
Angiographic and procedural characteristics
Diabetics 
n = 540 patients/ 894 
injuries
Non-diabetics 
n = 1,130 patients/ 1,685 
injuries
P 
0.38
Injury type, n (%) 
A 74 (8.3) 149 (8.9)
B1 256 (28.6) 470 (27.9)
B2 217 (24.3) 426 (25.3)
C 347 (38.8) 637 (37.9) 0.71
Initial TIMI flow, n (%) 
0 30 (3.4) 90 (5.4)
1 43 (4.8) 94 (5.1)
2 78 (8.7) 127 (7.6)
3 737 (82.4) 1.369 (81.5)
Treated arteries, n (%) 0.77
LMCA 14 (1.6) 29 (1.7) 0.25
LAD 378 (42.3) 752 (44.6) 0.28
LCx 224 (25.1) 390 (23.2) 0.65
RC 228 (25.5) 416 (24.7) 0.63
LITA graft, n (%) 4 (0.5) 10 (0.6) 0.14
SVB graft, n (%) 17 (1.9) 48 (2.9)
Characteristics of injury, n (%) 0.13
Thrombus 16 (1.8) 54 (3.2) 0.44
Calcification moderate/severe 146 (16.3) 255 (15.1) 0.13
Bifurcation 48 (5.4) 125 (7.4) 0.35
Ostial lesion 30 (3.4) 74 (6.6) 0.13
Chronic occlusion 34 (3.8) 95 (8.4)
Stenosis diameter, % 0.13
Pre 79.7 ± 11.3 81.0 ± 10.8 0.48
Post 1.1 ± 3.7 1.0 ± 5.1 0.85
Lesion length, mm 20.5 ± 7.0 20.3 ± 6.9 0.29
Direct stent, n (%) 265 (49.1) 845 (50.1) < 0.01
Stents per patient 1.7 ± 0.8 1.5 ± 0.7 0.28
Final TIMI flow, n (%) 
0 2 (0.2) 4 (0.2)
1 0 0
2 9 (1.0) 10 (0.6)
3 882 (98.7) 1,669 (99.2)
TIMI = Thrombolys in Myocardial Infarction; LMCA = left main coronary artery;LA D = left anterior descendent artery; LCx = left circumflex 
artery; RC = right coronary artery; LITA = left internal thoracic artery; SVB = saphenous vein bridge.
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RESULTS
During the reporting period, 1,670 patients underwent 
PCI only by DES implantation. Clinical, angiographic, 
and procedural characteristics are shown in Tables 1 
and 2, and in Figure 1. Of these patients, 540 (32.3%) 
had diabetes mellitus; 70.2% were under treatment with 
oral hypoglycaemic agents and 29.8% with insulin.
In-hospital outcomes
Angiographic success was achieved in 98.2% and 
procedural success in 96.7% of patients. The in-hospital 
results are shown in Table 3.
Primary endpoint
1,578 patients (94.5% of those eligible) had clini-
cal follow-up, with a mean time of 3.2 ± 2.5 years, 
and with a minimum of four months and a maximum 
of 10.3 years. The primary outcome occurred in 192 
(13.9%) patients; 130 deaths occurred (90 of cardiac 
causes; 5.7%), 32 AMI (2.0%), and 70 TVR (4.4%). 
The estimated survival free of the primary outcome 
was 81.6% in six years.
Diabetic patients had significantly lower survival 
free of events, compared to non-diabetic patients (79.4% 
vs. 82.6%; P = 0.02) (Figure 2). RR was 1.43 (95% CI, 
1.07 to 1.92) for events in diabetic patients (Figure 
3). However, after adjusting for confounder variables, 
the adjusted RR was 1.22 (95% CI, 0.89 to 1.69), not 
statistically significant.
When comparing diabetics taking insulin, diabet-
ics who were not taking insulin, and non-diabetics, 
the former showed survival free of events significantly 
lower than the other two groups, while diabetic patients 
who were not taking insulin showed similar behaviour 
to the non-diabetic ones (68.7% vs. 83.9% vs. 82.8%, 
respectively; P < 0.01). RR was 2.34 (95% CI, 1.62 to 
3.37) for diabetics using insulin, compared to the other 
patients (Figure 3). The adjusted RR was 1.72 (95% CI, 
1.13 to 2.63).
DISCUSSION
SAPPHIRE is the second published Brazilian registry 
evaluating the long-term follow-up of patients treated 
with DES. The DESIRE registry published its overall 
long-term results11 stratified by previous diabetes diag-
nosis.12 In the latter study, major adverse cardiac events 
occurred in 9.8% of diabetic patients and in 7% of 
non-diabetics, at a mean follow-up of 2.5 ± 1.4 years 
(P = 0.05). The observed differences in the incidence 
of events between the two registries are related to the 
different event definitions adopted, differences in clini-
cal and angiographic profile of patients, and different 
follow-up times.
In the present study, diabetic patients who were 
not using insulin had late evolution similar to that of 
non-diabetic patients. The more favorable results of these 
less complex diabetic patients can be attributed to the 
use of DES. The SES-SMART trial, which compared the 
use of sirolimus-eluting stents versus bare-metal stents, 
showed lower restenosis in diabetic patients who were 
not using insulin (17% vs. 63%; P = 0.01) – a benefit 
not observed in diabetic patients using insulin (40% 
vs. 64%; P = 0.4).13
The comparison of conventional stents and DES 
in 440 unselected patients found a reduction of car-
diac events in both groups of diabetic patients (with 
and without use of insulin), which was higher in the 
second group (1.9 times and 3.3 times, respectively).14 
TABLE 3 
Angiographic and clinical complications in  
in-hospital phase
Patients 
Diabetics  
n = 540
Non-diabetics  
n = 1,130 P
Angiographic 
complications, n (%) 
Failure of 
recanalization 
2 (0.4) 11 (1.0) 0.19
Acute occlusion 0 4 (0.3) 0.17
TIMI flow < 3 3 (0.8) 8 (0.7) 0.73
Stenosis > 20% 12 (1.0) 16 (3.0) 0.01
Major adverse 
cardiac events, n (%) 
Cardiac death 4 (0.7) 8 (0.7) 0.12
Non-fatal AMI 2 (0.4) 5 (0.5) 0.11
Urgent 
revascularization
5 (0.5) 0.85
TIMI = Thrombolys in Myocardial Infarction; AMI = acute 
myocardial infarction.
Figure 1 – Types of drug-eluting stents (DES) used in diabetic and 
non-diabetic patients. There was no significant difference in the use 
of any stent in diabetic and non-diabetic patients. 
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In another study involving 231 patients, late loss and 
binary restenosis were higher in diabetics using insu-
lin, compared to non-diabetics, whereas there was no 
difference between the group who were not taking 
insulin and the non-diabetic group.15 At one year of 
follow-up, a mean increase in target vessel failure and 
a trend towards higher mortality in the group taking 
insulin were observed, compared to non-diabetics (P 
= 0.06) – findings that were not present in the group 
that was not using insulin.
Diabetic patients have increased oxidative stress 
and inflammation, besides protein glycation; as a con-
sequence, they develop more extensive atherosclerosis, 
coagulation disorders, and a greater number of vulnerable 
atherosclerotic plaques. Notably, patients using insulin 
also exhibit increased synthesis of plasminogen activa-
tion inhibitor-1 (PAI-1), which favors atherothrombotic 
events and inhibits the remodelling and proteolysis that 
occur after arterial injury, with consequent accumula-
tion of extracellular matrix and neointimal hyperplasia, 
causing high rates of coronary restenosis.16
The SAPPHIRE registry shows rates of major ad-
verse cardiac events consistent with other registries.12,17 
According to the present results, it is concluded that 
the use of DES is of fundamental importance for the 
percutaneous treatment of coronary artery disease in 
diabetic patients, especially for those who do not use 
insulin, considering the reduction of risk of serious 
cardiac events to levels similar to those of non-diabetic 
patients.
CONCLUSIONS
In the present study, the use of DES was beneficial 
to all diabetics, especially those who did not use insulin.
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